Kurse werden geladen...
Prognose
| Kaufen | 7 |
| Halten | 1 |
| Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
NuCana Reports First Quarter 2025 Financial Results and Provides Business Update
Initiation of Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma» Mehr auf globenewswire.com
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025» Mehr auf globenewswire.com
Aurion Biotech Appoints Donald Munoz as Chief Financial Officer
SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced today that Donald Munoz is joining the Company as chief financial officer (CFO), reporting to Greg Kunst, chief executive officer (CEO). “We are delighted to welcome Don to our executive team,” said Greg Kunst, Aurion's CEO. “Don's track record of strategic and operational financial leadership, coupled.» Mehr auf businesswire.com
Unternehmenszahlen
| (EUR) | März 2025 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | - |
| Nettoeinkommen | −2,95 Mio | 63,11% |
| EBITDA | −3,25 Mio | 66,22% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 276,40k€ |
Anzahl Aktien | 6,06 Mio |
52 Wochen-Hoch/Tief | 9,19€ - 0,0281€ |
| Dividenden | Nein |
Beta | 1,25 |
KGV (PE Ratio) | −0,02 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,06 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
| Name | NuCana ADR Aktie |
| CEO | Hugh Stephen Griffith |
| Mitarbeiter | 20 |
Assets entdecken
Shareholder von NuCana ADR Aktie investieren auch in folgende Assets
